MEF2A, a gene associated with mitochondrial biogenesis, promotes drug resistance in gastric cancer.

Chemotherapeutic resistance is a major obstacle to the effectiveness of cisplatin-based chemotherapy for gastric cancer (GC), leading to treatment failure and poor survival rates. However, the underlying mechanisms are not fully understood. Our study demonstrated that the transcription factor myocyte enhancer factor 2A (MEF2A) plays a role in chemotherapeutic drug resistance by regulating the transcription of PGC1α and KEAP1, promoting mitochondrial biogenesis. It was found that increased MEF2A expression is linked with poor prognosis, cisplatin insensitivity, and mitochondrial function in GC. MEF2A overexpression significantly decreases GC cell sensitivity in vitro and in vivo , while MEF2A knockdown enhances the sensitivity to cisplatin. Mechanistically, MEF2A activates the transcription of PGC1α, leading to increased mitochondrial biogenesis. In addition, MEF2A inhibits KEAP1 transcription, reduces NRF2 ubiquitination degradation, and activates the KEAP1/NRF2 signaling pathway, which modulates the reactive oxygen species level. The present study identifies MEF2A as a new critical oncogene involved in GC chemoresistance, suggesting a novel therapeutic target for GC. [Display omitted] • Highly expressed MEF2A is associated with poor prognosis in gastric cancer. • MEF2A inhibits cisplatin sensitivity in vivo and in vitro. • MEF2A transcription activates PGC1α to promote mitochondrial biogenesis. • MEF2A transcriptional inhibition of KEAP1 leads to abnormal KEAP1/NRF2 signaling pathway. [ABSTRACT FROM AUTHOR]